Double-Blind_JJ Study_NN To_TO Evaluate_NP Flow_NP Cytometry_NP Analysis_NP of_IN Anti-Live_JJ Trypomastigote_NN Antibodies_NNS for_IN Monitoring_NP Treatment_NP Efficacy_NP in_IN Cases_NPS of_IN Human_NP Chagas_NP '_POS Disease_NN The_DT validation_NN of_IN flow_NN cytometry_NN analysis_NN of_IN anti-live_JJ trypomastigote_NN antibodies_NNS (_( FC-ALTA_NP )_) to_TO monitor_VB cure_NN after_IN treatment_NN of_IN Chagas_NP '_POS disease_NN was_VBD evaluated_VBN with_IN serum_NN samples_NNS from_IN treated_VBN and_CC nontreated_JJ chagasic_JJ patients_NNS ._SENT After_IN optimization_NN of_IN the_DT original_JJ technique_NN ,_, toward_IN better_JJR sensitivity_NN and_CC applicability_NN to_TO field_NN surveys_NNS ,_, we_PP design_VBP a_DT double_JJ blind_JJ study_NN of_IN 94_CD coded_VBN samples_NNS classified_VBN into_IN the_DT following_VBG categories_NNS :_: patients_NNS not_RB treated_VBD (_( NT_NP )_) and_CC patients_NNS treated_VBN but_CC not_RB cured_VBD (_( TNC_NP )_) ,_, both_CC presenting_VBG positive_JJ conventional_JJ serology_NN and_CC xenodiagnosis_NN ;_: patients_NNS treated_VBN and_CC cured_VBN (_( TC_NP )_) ,_, showing_VBG negative_JJ serology_NN and_CC xenodiagnosis_NN ;_: and_CC patients_NNS treated_VBN under_IN evaluation_NN (_( TUE_NP )_) ,_, who_WP presented_VBD positive_JJ or_CC oscillating_VBG conventional_JJ serology_NN (_( CSA_NP )_) but_CC negative_JJ xenodiagnosis_NN ._SENT Coded_VBN samples_NNS ,_, diluted_VBD 1:256_CD ,_, were_VBD assayed_VBN by_IN incubation_NN with_IN live_JJ cell_NN culture_NN trypomastigotes_NNS ,_, which_WDT were_VBD subsequently_RB stained_VBN with_IN fluorescein_NN isothiocyanate-conjugated_JJ anti-human_NN immunoglobulin_NN G_NP ,_, with_IN prior_JJ fixation_NN and_CC analysis_NN by_IN flow_NN cytometry_NN ._SENT The_DT results_NNS were_VBD expressed_VBN as_IN the_DT percentages_NNS of_IN positive_JJ fluorescent_JJ parasites_NNS (_( PPFP_NP )_) for_IN each_DT individual_JJ sample_NN ,_, establishing_VBG 20_CD %_NN PPFP_NN as_IN the_DT cutoff_NN between_IN negative_JJ and_CC positive_JJ results_NNS ._SENT Our_PP$ data_NNS demonstrated_VBD that_IN all_DT NT_NP and_CC TNC_NP presented_VBD positive_JJ results_NNS while_IN all_DT but_CC one_CD TC_NP had_VBD a_DT PPFP_NN lower_JJR than_IN 20_CD %_NN ._SENT Analysis_NN of_IN TUE_NP demonstrated_VBD a_DT wide_JJ degree_NN of_IN reactivity_NN ,_, with_IN PPFP_NP values_NNS that_WDT were_VBD negative_JJ (_( PPFP_NP <=_NN 20_CD %_NN )_) ,_, low_RB positive_JJ (_( 20_CD %_NN <_SYM PPFP_NP <=_50%), 50_CD %_NN )_) ._SENT As_IN TUE_NP with_IN negative_JJ PPFP_NP presented_VBD negative_JJ xenodiagnosis_NN and_CC positive_JJ or_CC oscillating_VBG CSA_NP ,_, they_PP were_VBD classified_VBN as_IN dissociated_VBN according_VBG to_TO the_DT criteria_NNS of_IN Krettli_NP and_CC Brener_NP (_( J._NP Immunol_NP ._SENT 128:2009-2012_CD ,_, 1982_CD )_) and_CC could_MD indeed_RB be_VB considered_VBN cured_VBN after_IN chemotherapy_NN ._SENT This_DT study_NN demonstrates_VBZ and_CC validates_VBZ the_DT use_NN of_IN FC-ALTA_NP to_TO easily_RB identify_VB anti-live_JJ trypomastigote_NN membrane-bound_JJ antibodies_NNS ,_, offering_VBG another_DT approach_NN for_IN investigating_VBG and_CC monitoring_VBG the_DT efficacy_NN of_IN specific_JJ chemotherapy_NN in_IN cases_NNS of_IN human_JJ Chagas_NP '_POS disease_NN ._SENT Chagas_NP '_POS disease_NN is_VBZ a_DT parasitic_JJ infection_NN caused_VBN by_IN the_DT protozoan_JJ Trypanosoma_NP cruzi_NNS ,_, which_WDT is_VBZ widespread_JJ in_IN South_NP and_CC Central_NP America_NP ,_, and_CC transmitted_VBD mainly_RB by_IN an_DT invertebrate_JJ vector_NN ,_, triatomine_NN ._SENT Although_IN autochthonous_JJ cases_NNS are_VBP rare_JJ in_IN other_JJ localities_NNS ,_, transmission_NN of_IN Chagas_NP '_POS disease_NN by_IN blood_NN transfusion_NN may_MD represent_VB an_DT increasing_VBG public_JJ health_NN problem_NN in_IN countries_NNS in_IN which_WDT Chagas_NP '_POS disease_NN is_VBZ not_RB endemic_JJ ._SENT Chemotherapy_NN with_IN nitroheterocyclic_JJ compounds_NNS has_VBZ been_VBN indicated_VBN for_IN the_DT treatment_NN of_IN acute_JJ cases_NNS ._SENT In_IN patients_NNS with_IN chronic_JJ disease_NN ,_, however_RB ,_, the_DT value_NN of_IN chemotherapy_NN is_VBZ still_RB controversial_JJ ._SENT So_RB far_RB ,_, it_PP has_VBZ been_VBN recommended_VBN for_IN the_DT treatment_NN of_IN patients_NNS with_IN recent_JJ chronic_JJ disease_NN who_WP have_VBP not_RB yet_RB developed_VBN clinical_JJ symptoms_NNS ._SENT One_CD of_IN the_DT major_JJ challenges_NNS regarding_VBG the_DT evaluation_NN of_IN treatment_NN effectiveness_NN is_VBZ the_DT lack_NN of_IN truthful_JJ laboratorial_JJ approaches_NNS for_IN use_NN as_IN tools_NNS for_IN cure_NN criteria_NNS ._SENT Two_CD categories_NNS of_IN tests_NNS are_VBP available_JJ ,_, including_VBG serological_JJ and_CC parasitological_JJ methods_NNS ._SENT Parasitological_JJ tests_NNS are_VBP based_VBN on_IN parasite_NN demonstration_NN by_IN hemoculture_NN ,_, xenodiagnosis_NN ,_, or_CC parasitological_JJ molecular_JJ test_NN (_( PCR_NP )_) ,_, whereas_IN serological_JJ methods_NNS evaluate_VBP the_DT presence_NN of_IN specific_JJ antibodies_NNS by_IN immunological_JJ methods_NNS ,_, such_JJ as_IN indirect_JJ hemagglutination_NN (_( IHA_NP )_) ,_, indirect_JJ immunofluorescence_NN assay_NN (_( IFA_NP )_) ,_, and_CC enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) ._SENT Using_VBG serological_JJ approaches_NNS ,_, Krettli_NP and_CC Brener_NP proposed_VBD that_DT sera_NN from_IN chronic_JJ chagasic_JJ patients_NNS present_JJ two_CD types_NNS of_IN anti-parasite_NN antibodies_NNS with_IN different_JJ functional_JJ activities_NNS named_VBN lytic_JJ antibodies_NNS (_( LA_NP )_) and_CC conventional_JJ serology_NN antibodies_NNS (_( CSA_NP )_) ._SENT LA_DT are_VBP associated_VBN with_IN resistance_NN in_IN active_JJ ongoing_JJ infection_NN and_CC can_MD be_VB detected_VBN by_IN complement-mediated_JJ lysis_NN (_( CoML_NP )_) and_CC indirect_JJ immunofluorescence_NN ,_, all_RB with_IN live_JJ trypomastigotes_NNS ._SENT On_IN the_DT other_JJ hand_NN ,_, CSA_NP are_VBP neither_RB associated_VBN with_IN resistance_NN nor_CC able_JJ to_TO bind_VB to_TO live_VB parasites_NNS ,_, but_CC they_PP do_VBP react_VB to_TO soluble_JJ or_CC fixed_VBN epimastigote_NN antigens_NNS and_CC are_VBP detected_VBN by_IN different_JJ immunological_JJ methods_NNS ._SENT Considering_VBG these_DT findings_NNS ,_, clinical_JJ trials_NNS have_VBP demonstrated_VBN that_IN LA_NP gradually_RB become_VBP negative_JJ after_IN treatment_NN ,_, whereas_IN CSA_NP can_MD remain_VB positive_JJ over_IN decades_NNS ._SENT So_RB it_PP has_VBZ been_VBN proposed_VBN that_IN the_DT cure_NN criterion_NN for_IN Chagas_NP '_POS disease_NN should_MD be_VB based_VBN on_IN either_DT negative_JJ parasitological_JJ tests_NNS or_CC the_DT absence_NN of_IN anti-live_JJ trypomastigote_NN antibodies_NNS (_( ALTA_NP )_) ._SENT A_DT flow_NN cytometric_JJ method_NN to_TO detect_VB ALTA_NP (_( FC-ALTA_NP )_) has_VBZ been_VBN previously_RB described_VBN as_IN a_DT new_JJ approach_NN for_IN monitoring_VBG the_DT efficacy_NN of_IN treatment_NN in_IN cases_NNS of_IN human_JJ Chagas_NP '_POS disease_NN ._SENT The_DT performance_NN of_IN FC-ALTA_NP has_VBZ been_VBN demonstrated_VBN to_TO be_VB comparable_JJ to_TO that_DT of_IN CoML_NP ,_, offering_VBG an_DT alternative_JJ method_NN for_IN easily_RB identifying_VBG anti-live_JJ T._NP cruzi_NNS membrane-bound_JJ antibodies_NNS ._SENT In_IN this_DT study_NN ,_, we_PP describe_VBP an_DT optimization_NN of_IN FC-ALTA_NP analysis_NN and_CC evaluate_VB its_PP$ performance_NN for_IN clinical_JJ studies_NNS ._SENT A_DT double-blind_JJ study_NN ,_, with_IN serum_NN samples_NNS from_IN treated_VBN and_CC nontreated_JJ chagasic_JJ patients_NNS ,_, was_VBD conducted_VBN to_TO validate_VB the_DT method_NN ,_, reemphasizing_VBG its_PP$ applicability_NN for_IN monitoring_VBG cure_NN after_IN treatment_NN of_IN Chagas_NP '_POS disease_NN ._SENT Moreover_RB ,_, the_DT data_NNS presented_VBD here_RB offer_VB an_DT optimization_NN of_IN the_DT original_JJ technique_NN ,_, making_VBG our_PP$ method_NN more_RBR sensitive_JJ and_CC applicable_JJ to_TO field_NN studies_NNS ._SENT Patients_NNS ._SENT |_SYM The_DT inclusion_NN of_IN all_DT subjects_NNS in_IN our_PP$ investigation_NN had_VBD the_DT approval_NN of_IN the_DT FIOCRUZ_NP Ethical_JJ Committee_NP (_( Brazilian_JJ Health_NP Ministry_NP )_) ._SENT In_IN this_DT study_NN ,_, we_PP analyzed_VBD 94_CD patients_NNS (_( 53_CD females_NNS and_CC 41_CD males_NNS )_) ranging_VBG in_IN age_NN from_IN 6_CD months_NNS to_TO 68_CD years_NNS assisted_VBN by_IN one_CD of_IN us_PP at_IN the_DT Faculdade_NP de_NP Medicina_NP ,_, Universidade_NP Federal_NP de_NP Goias_NP ,_, GoiAnia_NP ,_, Goias_NP ,_, Brazil_NP ._SENT Chagas_NP '_POS disease_NN diagnosis_NN was_VBD established_VBN in_IN all_DT patients_NNS by_IN positive_JJ xenodiagnosis_NN and_CC three_CD positive_JJ serological_JJ tests_NNS ,_, including_VBG IHA_NP ,_, IFA_NP ,_, and_CC ELISA_NP ._SENT All_DT patients_NNS in_IN the_DT acute_JJ (_( n_NN =_SYM 13_CD )_) and_CC subacute_JJ (_( n_NN =_SYM 3_LS )_) phases_NNS were_VBD treated_VBN with_IN benznidazole_NN (_( BZ_NP )_) (_( 60_CD mg/kg_NN of_IN body_NN weight/day_NN for_IN 60_CD days_NNS )_) ._SENT Patients_NNS in_IN the_DT chronic_JJ phase_NN (_( n_NN =_SYM 78_CD )_) were_VBD treated_VBN with_IN BZ_NP (_( n_NN =_SYM 44_CD )_) ,_, allopurinol_NN (_( n_NN =_SYM 3_CD )_) ,_, nifurtimox_NP (_( n_NN =_SYM 3_CD )_) ,_, or_CC BW349C59_NP (_( n_NN =_SYM 6_CD )_) or_CC not_RB treated_VBD (_( n_NN =_SYM 22_CD )_) ._SENT In_IN this_DT study_NN ,_, we_PP did_VBD not_RB focus_VB on_IN the_DT efficacy_NN of_IN the_DT different_JJ therapeutic_JJ schemes_NNS used_VBN since_IN it_PP was_VBD not_RB the_DT major_JJ goal_NN of_IN our_PP$ present_JJ investigation_NN ._SENT After_IN clinical_JJ ,_, parasitological_JJ ,_, and_CC serological_JJ follow-up_NN studies_NNS ,_, ranging_VBG from_IN 3_CD to_TO 26_CD years_NNS ,_, patients_NNS were_VBD classified_VBN into_IN three_CD different_JJ categories_NNS :_: not_RB treated_VBD (_( NT_NP )_) (_( n_NN =_SYM 22_CD )_) ,_, all_DT patients_NNS with_IN chronic_JJ disease_NN ;_: treated_VBN but_CC not_RB cured_VBD (_( TNC_NP )_) (_( n_NN =_SYM 19_CD )_) ,_, 4_CD patients_NNS with_IN acute-_NN and_CC 15_CD patients_NNS with_IN chronic-phase_NN disease_NN ;_: treated_VBN and_CC cured_VBN (_( TC_NP )_) (_( n_NN =_SYM 25_CD )_) ,_, 8_CD patients_NNS with_IN acute-_NN ,_, 3_CD patients_NNS with_IN subacute-_NN ,_, and_CC 14_CD patients_NNS with_IN chronic-phase_NN disease_NN ;_: and_CC treated_VBN under_IN evaluation_NN (_( TUE_NP )_) (_( n_NN =_SYM 28_CD )_) ,_, 1_CD patient_NN with_IN acute-_NN and_CC 27_CD patients_NNS with_IN chronic-phase_NN disease_NN ._SENT NT_NP and_CC TNC_NP patients_NNS had_VBD positive_JJ results_NNS on_IN both_DT serological_JJ and_CC parasitological_JJ tests_NNS ._SENT Patients_NNS were_VBD considered_VBN TC_NP only_RB when_WRB both_DT tests_NNS ,_, serological_JJ and_CC parasitological_JJ ,_, were_VBD consistently_RB and_CC repeatedly_RB (_( at_IN least_JJS eight_CD times_NNS )_) negative_JJ ._SENT Patients_NNS presenting_VBG with_IN positive_JJ (_( n_NN =_SYM 17_CD )_) or_CC oscillating_VBG (_( n_NN =_SYM 11_CD )_) serology_NN with_IN negative_JJ parasitological_JJ tests_NNS were_VBD considered_VBN TUE_NP ._SENT Samples_NNS were_VBD coded_VBN and_CC stored_VBN pure_JJ at_IN -20C_NN or_CC in_IN 50_CD %_NN glycerol_NN at_IN room_NN temperature_NN ._SENT Conventional_JJ serological_JJ tests_NNS ._SENT |_SYM Three_CD kinds_NNS of_IN serological_JJ tests_NNS were_VBD performed_VBN as_IN recommended_VBN by_IN the_DT World_NP Health_NP Organization_NP :_: IHA_NP (_( Imunoserum_NP ,_, Sao_NP Paulo_NP ,_, Brazil_NP )_) ,_, IFA_NP (_( Biolab_NP ,_, Rio_NP de_NP Janeiro_NP ,_, Brazil_NP )_) ,_, and_CC ELISA_NP (_( Abbott_NP )_) ._SENT At_IN the_DT beginning_NN of_IN the_DT study_NN ,_, we_PP used_VBD the_DT complement_NN fixation_NN reaction_NN ,_, which_WDT was_VBD available_JJ at_IN that_DT time_NN ,_, to_TO screen_VB some_DT patients_NNS ._SENT Xenodiagnosis_NN ._SENT |_SYM Xenodiagnosis_NN was_VBD performed_VBN on_IN all_DT patients_NNS before_IN and_CC after_IN treatment_NN as_IN described_VBN by_IN Cerisola_NP et_FW al._FW by_IN using_VBG triatomine_NN from_IN Dipetalogaster_NP maximus_NN and_CC Triatoma_NN infestans_NNS according_VBG to_TO availability_NN ._SENT Forty_NN triatomines_NNS ,_, after_IN a_DT 15-day_JJ fast_JJ ,_, were_VBD allowed_VBN to_TO feed_VB on_IN each_DT patient_NN for_IN 30_CD min_NN ._SENT Microscopic_JJ examination_NN of_IN intestinal_JJ contents_NNS was_VBD carried_VBN out_IN 30_CD and_CC 60_CD days_NNS after_IN feeding_NN ._SENT The_DT number_NN of_IN xenodiagnoses_NNS per_IN patient_NN ranged_VBN from_IN 8_CD (_( 320_CD triatomines_NNS )_) to_TO 114_CD (_( 4,500_CD triatomines_NNS )_) ._SENT Cell_NN line_NN and_CC parasites_NNS ._SENT |_SYM NTCT_NP clone_NN 929_CD cells_NNS (_( L929_NP ,_, ATCC_NP CCL_NP 1_CD )_) were_VBD maintained_VBN in_IN our_PP$ laboratory_NN by_IN serial_JJ passages_NNS and_CC frozen_VBN in_IN liquid_JJ nitrogen_NN ._SENT For_IN the_DT assays_NNS ,_, 5_CD x_SYM 105_CD L929_NP cells_NNS were_VBD seeded_VBN in_IN tissue_NN culture_NN flasks_NNS (_( 25_CD or_CC 75_CD cm2_NN ,_, Falcon_NP ;_: Becton_NP Dickinson_NP ,_, San_NP Jose_NP ,_, Calif._NP )_) with_IN 10_CD ml_NN of_IN RPMI_NP medium_NN (_( GIBCO_NP ,_, Grand_NP Island_NP ,_, N.Y._NP )_) containing_VBG 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NP )_) and_CC incubated_VBN at_IN 37C_JJ in_IN humidified_VBN air_NN containing_VBG 5_CD %_NN CO2_NN ._SENT After_IN 2_CD or_CC 3_CD days_NNS ,_, the_DT monolayer_NN was_VBD infected_VBN with_IN 3_CD x_NN 106_CD to_TO 7_CD x_NN 106_CD trypomastigotes_NNS of_IN T._NP cruzi_NNS strain_VBP CL_NP ._SENT Trypomastigotes_NNS were_VBD obtained_VBN initially_RB from_IN infected_JJ mice_NNS and_CC subsequently_RB from_IN the_DT supernatant_JJ of_IN another_DT infected_JJ monolayer_NN ._SENT Infected_JJ cells_NNS were_VBD washed_VBN daily_RB with_IN RPMI-5_NP %_NN FBS_NP ._SENT The_DT cultures_NNS were_VBD maintained_VBN in_IN RPMI_NP and_CC 10_CD %_NN FBS_NP at_IN 33C_NP ,_, 5_CD %_NN CO2_NN ,_, and_CC 95_CD %_NN humidity_NN ._SENT After_IN 5_CD to_TO 7_CD days_NNS of_IN incubation_NN ,_, the_DT trypomastigotes_NNS started_VBN being_VBG released_VBN into_IN the_DT supernatant_JJ ._SENT The_DT cell_NN culture_NN was_VBD transferred_VBN to_TO a_DT 50-ml_JJ tube_NN and_CC centrifuged_VBN at_IN low_JJ speed_NN (_( 100_CD x_SYM g_NN for_IN 10_CD min_NN at_IN room_NN temperature_NN )_) to_TO remove_VB cell_NN debris_NN and_CC some_DT contaminating_VBG amastigotes_NNS ._SENT Trypomastigotes_NNS recovered_VBD from_IN the_DT supernatant_JJ were_VBD washed_VBN three_CD times_NNS (_( 1,000_CD x_SYM g_NN for_IN 15_CD min_NN at_IN 4C_JJ )_) and_CC resuspended_JJ in_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) and_CC 10_CD %_NN FBS_NP at_IN a_DT concentration_NN of_IN 1_CD x_SYM 106_CD parasites/ml_NN ._SENT A_DT 50-mul_NP sample_NN was_VBD used_VBN for_IN FC-ALTA_NP ._SENT FC-ALTA_NP ._SENT |_SYM The_DT immunofluorescence_NN reaction_NN was_VBD performed_VBN as_IN described_VBN by_IN Martins-Filho_NP et_FW al._FW ,_, modified_VBN as_RB follows_VBZ ._SENT Live_JJ trypomastigotes_NNS (_( 500,000_CD )_) were_VBD incubated_VBN at_IN 37C_JJ for_IN 30_CD min_NN in_IN the_DT presence_NN of_IN a_DT 1:256_CD final_JJ dilution_NN of_IN serum_NN (_( whole_JJ or_CC diluted_VBN 1:1_CD in_IN glycerol_NN )_) ,_, using_VBG a_DT coded_VBN serum_NN sample_NN ._SENT After_IN incubation_NN with_IN sera_NN ,_, parasites_NNS were_VBD washed_VBN once_RB with_IN PBS_NP containing_VBG 10_CD %_NN FBS_NP ._SENT Parasite_NN suspensions_NNS were_VBD reincubated_VBN at_IN 4C_JJ for_IN 1_CD h_NN or_CC 37C_JJ for_IN 30_CD min_NN in_IN the_DT dark_NN in_IN the_DT presence_NN of_IN fluorescein_NN isothiocyanate_NN (FITC)-conjugated_JJ anti-human_NN immunoglobulin_NN G_NP (_( IgG_NP )_) antibody_NN (_( anti-whole_NN molecule_NN )_) (_( Sigma_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) diluted_VBD 1:400_CD in_IN PBS-10_NP %_NN FBS_NP ._SENT The_DT use_NN of_IN different_JJ temperatures_NNS and_CC times_NNS of_IN incubation_NN with_IN FITC-conjugated_NP anti-human_NP IgG_NP antibody_NN represented_VBD the_DT major_JJ change_NN from_IN the_DT original_JJ method_NN described_VBN by_IN Martins-Filho_NP et_FW al._FW ,_, where_WRB incubation_NN was_VBD performed_VBN only_RB at_IN 4C_JJ for_IN 60_CD min_NN ._SENT Each_DT assay_NN included_VBD an_DT internal_JJ control_NN of_IN nonspecific_JJ binding_NN as_IN well_RB as_RB positive_JJ and_CC negative_JJ controls_NNS ._SENT To_TO monitor_VB unspecific_JJ binding_NN ,_, parasites_NNS not_RB exposed_VBN to_TO human_JJ serum_NN were_VBD incubated_VBN with_IN FITC-conjugated_NP anti-human_NP IgG_NP ._SENT Positive_JJ controls_NNS included_VBD sera_NN from_IN NT_JJ chagasic_JJ patients_NNS ,_, whereas_IN samples_NNS from_IN uninfected_JJ individuals_NNS were_VBD included_VBN as_IN negative_JJ controls_NNS ._SENT After_IN being_VBG stained_VBN ,_, labeled_VBD parasites_NNS were_VBD washed_VBN with_IN PBS-10_NP %_NN FBS_NP and_CC fixed_VBN on_IN ice_NN for_IN 30_CD min_NN with_IN a_DT fix_NN solution_NN (_( 10_CD g_NN of_IN paraformaldehyde_NN per_IN liter_NN ,_, 1_CD %_NN sodium_NN cacodylate_NN ,_, 6.65_CD g_NN of_IN sodium_NN chloride_NN per_IN liter_NN ,_, and_CC 0.01_CD %_NN sodium_NN azide_NN ,_, pH_NN 7.2_CD )_) ._SENT Flow_NN cytometry_NN analysis_NN was_VBD performed_VBN up_RP to_TO 24_CD h_NN after_IN parasite_NN fixation_NN ._SENT FACScan_NP data_NNS storage_NN and_CC analysis_NN ._SENT |_SYM Flow-cytometric_NP measurements_NNS were_VBD performed_VBN on_IN a_DT Becton_NP Dickinson_NP FACScan_NP interfaced_VBD to_TO an_DT Apple_NP Quadra_NP FACStation_NP ._SENT CellQuest_NP software_NN was_VBD used_VBN for_IN both_DT data_NNS storage_NN and_CC analysis_NN ._SENT Trypomastigotes_NNS were_VBD identified_VBN based_VBN on_IN their_PP$ specific_JJ forward_RB (_( FSC_NP )_) and_CC side_NN (_( SSC_NP )_) laser-scattering_NN properties_NNS ._SENT Following_VBG FSC_NN and_CC SSC_NN adjustments_NNS ,_, parasites_NNS were_VBD localized_VBN on_IN FSC_NP (_( size_NN )_) by_IN SSC_NP (_( internal_JJ complexity-granularity_NN )_) dot_VBP plot_NN distribution_NN ._SENT Parasites_NNS were_VBD then_RB selected_VBN by_IN gating_VBG on_IN the_DT FSC_NN by_IN SSC_NP dot_VBP plot_NN distribution_NN ._SENT An_DT average_NN of_IN 8,000_CD to_TO 9,000_CD gated_VBN trypomastigotes_NNS was_VBD analyzed_VBN for_IN relative_JJ fluorescence_NN intensity_NN by_IN using_VBG single_JJ FITC_NP histograms_NNS for_IN each_DT individual_JJ sample_NN ._SENT A_DT control_NN marker_NN of_IN up_IN to_TO 2_CD %_NN of_IN the_DT parasites_NNS that_WDT were_VBD fluorescence_NN positive_JJ was_VBD set_VBN up_RP on_IN the_DT FITC-conjugated_JJ internal_JJ control_NN histogram_NN ._SENT This_DT marker_NN was_VBD used_VBN to_TO determine_VB the_DT percentage_NN of_IN positive_JJ fluorescent_JJ parasites_NNS (_( PPFP_NP )_) for_IN each_DT sample_NN ._SENT Figures_NNS show_VBP representative_JJ histograms_NNS for_IN the_DT negative_JJ and_CC positive_JJ controls_NNS ,_, respectively_RB ._SENT Data_NP analysis_NN was_VBD performed_VBN by_IN establishing_VBG 20_CD %_NN PPFP_NN as_IN the_DT cutoff_NN between_IN negative_JJ and_CC positive_JJ results_NNS as_IN described_VBN by_IN Martins-Filho_NP et_FW al._FW ._SENT Thus_RB ,_, samples_NNS were_VBD considered_VBN positive_JJ when_WRB the_DT PPFP_NP was_VBD >20_JJ %_NN and_CC negative_NN when_WRB the_DT PPFP_NP was_VBD <=20_JJ %_NN ._SENT Positive_JJ results_NNS were_VBD additionally_RB classified_VBN according_VBG to_TO the_DT method_NN of_IN Cordeiro_NP et_FW al._FW as_IN low_JJ positive_JJ (_( 20_CD %_NN <_SYM PPFP_NP <=_50%) 50_CD %_NN )_) ._SENT Statistics_NNS ._SENT |_SYM Statistical_NP analysis_NN was_VBD performed_VBN using_VBG one-way_JJ analysis_NN of_IN variance_NN followed_VBN by_IN Student_NP 's_POS t_NN test_NN ._SENT Differences_NNS were_VBD considered_VBN significant_JJ when_WRB the_DT P_NN value_NN was_VBD <0.05_JJ ._SENT FIG._NN 1_CD ._SENT |_SYM FC-ALTA_NP ._SENT FC-ALTA_NP ._SENT (_( a_DT )_) Dot_NP plot_NN analysis_NN of_IN a_DT representative_JJ trypomastigote_NN distribution_NN (_( R1_NP )_) based_VBN on_IN size_NN and_CC granularity_NN ._SENT Single_JJ histograms_NNS represent_VBP PPFP_NP values_NNS for_IN FITC-conjugated_NP anti-human_NP IgG_NP internal_JJ control_NN (_( b_LS )_) ,_, negative_JJ control_NN (_( c_LS )_) ,_, and_CC positive_JJ control_NN (_( d_LS )_) ._SENT TABLE_NN 1_CD |_SYM Patients_NNS ,_, conventional_JJ serology_NN ,_, and_CC xenodiagnosis_NN Optimization_NP of_IN original_JJ method_NN for_IN FC-ALTA_NP ._SENT (_( i_NP )_) Effect_NN of_IN incubation_NN temperature_NN on_IN PPFP_NP values_NNS ._SENT |_SYM In_IN order_NN to_TO evaluate_VB the_DT effect_NN of_IN incubation_NN conditions_NNS on_IN the_DT performance_NN of_IN FITC-conjugated_NP anti-human_NP IgG_NP antibody_NN binding_NN ,_, we_PP performed_VBD a_DT parallel_JJ study_NN in_IN which_WDT a_DT 1-h_NP incubation_NN at_IN 4C_NP was_VBD compared_VBN to_TO a_DT 30-min_JJ incubation_NN at_IN 37C_JJ ._SENT Figure_NN shows_VBZ representative_JJ histogram_NN analyses_NNS demonstrating_VBG that_IN the_DT latter_JJ condition_NN led_VBD to_TO higher_JJR PPFP_NP values_NNS for_IN samples_NNS from_IN one_CD NT_JJ patient_NN ,_, whereas_IN no_DT change_NN was_VBD detected_VBN for_IN a_DT sample_NN from_IN a_DT TC_NP patient_NN ._SENT Using_VBG a_DT range_NN of_IN samples_NNS ,_, our_PP$ data_NNS demonstrated_VBD that_DT incubation_NN of_IN parasites_NNS for_IN 30_CD min_NN at_IN 37C_JJ increases_NNS the_DT sensitivity_NN of_IN FC-ALTA_NP (_( P_NN =_SYM 0.0007_CD for_IN NT_JJ patients_NNS and_CC P_NN =_SYM 0.0001_CD for_IN TNC_NP patients_NNS )_) with_IN no_DT effect_NN on_IN its_PP$ ability_NN to_TO discriminate_VB samples_NNS with_IN PPFP_JJ values_NNS of_IN <=20_JJ %_NN (_( P_NN =_SYM 0.68_CD )_) ._SENT Therefore_RB ,_, we_PP have_VBP adjusted_VBN this_DT condition_NN in_IN the_DT original_JJ method_NN in_IN order_NN to_TO improve_VB the_DT sensitivity_NN of_IN FC-ALTA_NP ._SENT (_( ii_NP )_) Comparison_NP of_IN PPFP_NP values_NNS between_IN pure_JJ and_CC GPS_NP ._SENT |_SYM With_IN the_DT purpose_NN of_IN fitting_VBG the_DT method_NN for_IN field_NN studies_NNS ,_, in_IN which_WDT storage_NN of_IN frozen_JJ samples_NNS (_( FS_NP )_) may_MD not_RB be_VB possible_JJ ,_, we_PP tested_VBD the_DT applicability_NN of_IN our_PP$ method_NN to_TO glycerol-preserved_JJ samples_NNS (_( GPS_NP )_) that_WDT can_MD easily_RB be_VB maintained_VBN at_IN room_NN temperature_NN ._SENT Parallel_JJ studies_NNS which_WDT used_VBD 70_CD pairs_NNS of_IN FS_NP and_CC GPS_NP samples_NNS were_VBD carried_VBN out_RP ,_, and_CC the_DT PPFP_NP values_NNS for_IN each_DT individual_JJ sample_NN are_VBP presented_VBN in_IN Fig._NN ._SENT Data_NP analysis_NN was_VBD performed_VBN by_IN grouping_VBG the_DT samples_NNS based_VBN on_IN the_DT PPFP_NP values_NNS obtained_VBN with_IN FS_NN as_IN negative_JJ (_( PPFP_NP <=_NN 20_CD %_NN )_) ,_, low_RB positive_JJ (_( 20_CD %_NN <_SYM PPFP_NP <=_50%), 50_CD %_NN )_) followed_VBN by_IN comparison_NN with_IN the_DT PPFP_NP values_NNS obtained_VBN with_IN GPS_NP ._SENT One_CD out_RB of_IN 29_CD samples_NNS with_IN negative_JJ results_NNS (_( PPFP_NP =_SYM 20.0_CD %_NN )_) became_VBD low_RB positive_JJ (_( PPFP_NP =_SYM 25.0_CD %_NN )_) when_WRB tested_VBN as_IN GPS_NP ._SENT Two_CD out_RB of_IN 11_CD samples_NNS with_IN low-positive_JJ results_NNS showed_VBD a_DT distinct_JJ result_NN when_WRB tested_VBN as_IN GPS_NP ._SENT One_PP became_VBD negative_JJ (_( PPFP_NP =_SYM 26.0_CD to_TO 17.0_CD %_NN )_) and_CC another_DT one_CD became_VBD high_RB positive_JJ (_( PPFP_NP =_SYM 50.0_CD to_TO 66.0_CD %_NN )_) ._SENT No_DT changes_NNS were_VBD observed_VBN in_IN the_DT performance_NN of_IN FC-ALTA_NP for_IN all_DT 40_CD samples_NNS that_WDT showed_VBD high-positive_JJ results_NNS ._SENT Statistical_JJ analysis_NN did_VBD not_RB show_VB any_DT differences_NNS between_IN the_DT mean_JJ PPFP_NP values_NNS obtained_VBN from_IN GPS_NP and_CC FS_NP (_( P_NN =_SYM 0.89_CD for_IN results_NNS with_IN PPFP_NP <=_NN 20_CD %_NN ,_, P_NN =_SYM 0.66_CD for_IN results_NNS with_IN 20_CD %_NN <_SYM PPFP_NP <=_50%, 50_CD %_NN )_) ._SENT Performance_NN of_IN FC-ALTA_NP with_IN treated_VBN and_CC nontreated_JJ patient_JJ samples_NNS ._SENT (_( i_NP )_) PPFP_NP values_NNS from_IN NT_NP and_CC TNC_NP patients_NNS ._SENT |_SYM PPFP_NP values_NNS from_IN chagasic_JJ patients_NNS with_IN positive_JJ serology_NN and_CC xenodiagnosis_NN are_VBP presented_VBN in_IN Fig._NN ._SENT Our_PP$ data_NNS demonstrated_VBD that_IN all_DT NT_JJ patients_NNS showed_VBD positive_JJ PPFP_NP values_NNS ._SENT Moreover_RB ,_, it_PP was_VBD interesting_JJ that_IN NT_JJ samples_NNS were_VBD always_RB high_RB positive_JJ (_( PPFP_NP >_SYM 50_CD %_NN )_) ._SENT The_DT TNC_NP patients_NNS were_VBD subdivided_VBN into_IN two_CD groups_NNS as_IN they_PP received_VBD treatment_NN during_IN the_DT acute_JJ or_CC chronic_JJ phase_NN of_IN the_DT disease_NN ._SENT In_IN the_DT same_JJ manner_NN ,_, all_DT TNC_NP patients_NNS presented_VBD PPFP_NP values_VBZ greater_JJR than_IN the_DT 20_CD %_NN cutoff_NN ,_, and_CC then_RB they_PP did_VBD not_RB differ_VB from_IN NT_JJ patients_NNS ._SENT However_RB ,_, in_IN this_DT group_NN we_PP found_VBD two_CD low-positive_JJ samples_NNS with_IN PPFP_JJ values_NNS of_IN >20_JJ %_NN and_CC <=50%_(samples 50_CD %_NN )_) ,_, 9_CD samples_NNS classified_VBN as_IN low_JJ positive_JJ (_( 20_CD %_NN <_SYM PPFP_JJ <=_NN 50_CD %_NN )_) ,_, and_CC 7_CD samples_NNS presenting_VBG negative_JJ results_NNS (_( PPFP_NP <=_20%) 50_CD %_NN )_) ._SENT Patients_NNS with_IN more_JJR than_IN 10_CD years_NNS of_IN follow-up_NN after_IN treatment_NN presented_VBD a_DT wide_JJ range_NN of_IN results_NNS ._SENT The_DT frequency_NN of_IN samples_NNS with_IN high_JJ positive_JJ results_NNS dropped_VBD to_TO 31.5_CD %_NN (_( 6_CD of_IN 19_CD )_) ,_, and_CC the_DT frequency_NN of_IN low-positive_JJ and_CC negative_JJ results_NNS increased_VBD to_TO 31.5_CD %_NN (_( 6_CD of_IN 19_CD )_) and_CC 37.0_CD %_NN (_( 7_CD of_IN 19_CD )_) ,_, respectively_RB ._SENT Statistical_JJ analysis_NN demonstrated_VBD that_IN results_NNS for_IN patients_NNS in_IN the_DT <=10_years 10_CD years_NNS after_IN treatment_NN group_NN (_( P_NN <_SYM 0.05_CD )_) ._SENT To_TO further_RBR address_VB the_DT differential_JJ reactivity_NN of_IN the_DT TUE_NP patient_NN group_NN ,_, we_PP subdivided_VBD the_DT patients_NNS based_VBN on_IN their_PP$ results_NNS from_IN CSA_NP analysis_NN ._SENT Then_RB the_DT PPFP_NP values_NNS from_IN patients_NNS with_IN positive_JJ CSA_NP and_CC those_DT with_IN oscillating_VBG CSA_NP were_VBD compared_VBN ._SENT The_DT data_NNS demonstrated_VBD that_IN both_DT subgroups_NNS had_VBD negative_JJ ,_, low-positive_JJ ,_, and_CC high-positive_JJ results_NNS ._SENT The_DT percentages_NNS of_IN samples_NNS with_IN negative_JJ ,_, low-positive_JJ ,_, and_CC high-positive_JJ PPFP_NP values_NNS were_VBD 36.5_CD %_NN (_( 4_CD of_IN 11_CD )_) ,_, 36.5_CD %_NN (_( 4_CD of_IN 11_CD )_) ,_, and_CC 27.0_CD %_NN (_( 3_CD of_IN 11_CD )_) for_IN patients_NNS with_IN oscillating_VBG CSA_NP and_CC 18.0_CD %_NN (_( 3_CD of_IN 17_CD )_) ,_, 29.0_CD %_NN (_( 5_CD of_IN 17_CD )_) ,_, and_CC 53.0_CD %_NN (_( 9_CD of_IN 17_CD )_) for_IN those_DT with_IN positive_JJ CSA_NP ,_, respectively_RB ._SENT Interestingly_RB ,_, the_DT frequency_NN of_IN high-positive_JJ results_NNS was_VBD higher_JJR within_IN the_DT group_NN with_IN positive_JJ CSA_NP (_( 53.0_CD versus_IN 27.0_CD %_NN )_) ._SENT Together_RB ,_, our_PP$ data_NNS support_VBP the_DT hypothesis_NN that_IN high-positive_JJ results_NNS with_IN FC-ALTA_NP are_VBP in_IN general_NN associated_VBN with_IN positive_JJ CSA_NP ,_, regardless_RB of_IN the_DT clinical_JJ group_NN analyzed_VBN (_( NT_NP ,_, TNC_NP ,_, or_CC TUE_NP )_) ._SENT FIG._NN 2_CD ._SENT |_SYM Representative_NP histograms_NNS showing_VBG effect_NN of_IN incubation_NN temperature_NN on_IN PPFP_NP values_NNS ._SENT Representative_JJ histograms_NNS showing_VBG effect_NN of_IN incubation_NN temperature_NN on_IN PPFP_NP values_NNS ._SENT Parasites_NNS were_VBD incubated_VBN in_IN parallel_JJ study_NN with_IN a_DT 1:256_CD dilution_NN of_IN PBS-10_NP %_NN FBS-diluted_NP human_JJ sera_NN (_( from_IN NT_NP and_CC TC_NP patients_NNS )_) followed_VBN by_IN a_DT 1-h_NP incubation_NN at_IN 4C_JJ (_( a_DT )_) or_CC a_DT 30-min_JJ incubation_NN at_IN 37C_JJ (_( b_LS )_) with_IN FITC-conjugated_NP anti-human_NP IgG_NP (_( whole-molecule_NN )_) antibody_NN ._SENT (_( c_LS )_) A_DT range_NN of_IN samples_NNS were_VBD tested_VBN for_IN both_DT protocols_NNS (_( -4C_NN for_IN 60_CD min_NN and_CC 37C_JJ for_IN 30_CD min_NN [_SYM *_SYM ]_SYM )_) ,_, including_VBG samples_NNS from_IN the_DT NT_JJ (_( n_NN =_SYM 12_CD )_) ,_, TNC_NP (_( n_NN =_SYM 9_CD )_) ,_, and_CC TC_NP (_( n_NN =_SYM 4_LS )_) patient_JJ groups_NNS ._SENT Statistical_JJ analysis_NN demonstrated_VBD significant_JJ differences_NNS between_IN PPFP_NP values_NNS obtained_VBN at_IN 37C_JJ for_IN 60_CD min_NN in_IN comparison_NN to_TO those_DT obtained_VBN at_IN 4C_JJ for_IN 60_CD min_NN for_IN the_DT NT_NP and_CC TNC_NP patient_NN groups_NNS but_CC not_RB for_IN the_DT TC_NP patient_NN group_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Comparison_NP of_IN PPFP_NP values_NNS between_IN pure_JJ and_CC GPS_NP ._SENT Comparison_NN of_IN PPFP_NP values_NNS between_IN pure_JJ and_CC GPS_NP ._SENT Parallel_JJ studies_NNS with_IN pairs_NNS of_IN FS_JJ (_( *_SYM )_) and_CC GPS_NP samples_NNS were_VBD carried_VBN out_RP ,_, and_CC the_DT results_NNS were_VBD presented_VBN as_IN PPFP_NP values_NNS ._SENT Samples_NNS were_VBD grouped_VBN based_VBN on_IN the_DT PPFP_NP values_NNS obtained_VBN with_IN FS_NN followed_VBN by_IN comparison_NN with_IN the_DT PPFP_NP values_NNS obtained_VBN with_IN GPS_NP ._SENT No_DT significant_JJ differences_NNS were_VBD observed_VBN between_IN mean_JJ PPFP_NP values_NNS obtained_VBN from_IN FS_NP and_CC GPS_NP ._SENT FIG._NN 4_CD ._SENT |_SYM Analysis_NP of_IN PPFP_NP values_NNS from_IN patients_NNS with_IN positive_JJ xenodiagnosis_NN and_CC positive_JJ conventional_JJ serology_NN ._SENT Analysis_NN of_IN PPFP_NP values_NNS from_IN patients_NNS with_IN positive_JJ xenodiagnosis_NN and_CC positive_JJ conventional_JJ serology_NN ._SENT The_DT performance_NN of_IN FC-ALTA_NP with_IN samples_NNS from_IN the_DT NT_JJ (_( a_DT )_) and_CC TNC_NP (_( b_LS )_) patient_JJ groups_NNS was_VBD investigated_VBN by_IN using_VBG FS_NN ,_, and_CC data_NNS analysis_NN was_VBD performed_VBN by_IN establishing_VBG a_DT 20_CD %_NN PPFP_NN value_NN as_IN the_DT cutoff_NN between_IN negative_JJ and_CC positive_JJ results_NNS ,_, as_RB described_VBN by_IN Martins-Filho_NP et_FW al._FW ._SENT Positive_JJ results_NNS were_VBD additionally_RB classified_VBN according_VBG to_TO the_DT method_NN of_IN Cordeiro_NP et_FW al._FW as_IN low_JJ positive_JJ (_( 20_CD %_NN <_SYM PPFP_NP <=_50%) 50_CD %_NN )_) ._SENT The_DT TNC_NP patients_NNS were_VBD subdivided_VBN into_IN two_CD groups_NNS ,_, as_IN they_PP received_VBD treatment_NN during_IN the_DT acute_JJ (_( A_NP )_) or_CC chronic_JJ (_( C_NP )_) phase_NN of_IN the_DT disease_NN ._SENT FIG._NN 5_CD ._SENT |_SYM Analysis_NP of_IN PPFP_NP values_NNS from_IN patients_NNS with_IN negative_JJ xenodiagnosis_NN and_CC negative_JJ conventional_JJ serology_NN ._SENT Analysis_NN of_IN PPFP_NP values_NNS from_IN patients_NNS with_IN negative_JJ xenodiagnosis_NN and_CC negative_JJ conventional_JJ serology_NN ._SENT The_DT performance_NN of_IN FC-ALTA_NP for_IN samples_NNS from_IN the_DT TC_NP patient_NN group_NN was_VBD investigated_VBN by_IN using_VBG FS_NN ,_, and_CC data_NNS analysis_NN was_VBD performed_VBN by_IN establishing_VBG a_DT 20_CD %_NN PPFP_NN value_NN as_IN the_DT cutoff_NN between_IN negative_JJ and_CC positive_JJ results_NNS ,_, as_RB described_VBN by_IN Martins-Filho_NP et_FW al._FW ._SENT Positive_JJ results_NNS were_VBD additionally_RB classified_VBN according_VBG to_TO the_DT method_NN of_IN Cordeiro_NP et_FW al._FW as_IN low_JJ positive_JJ (_( 20_CD %_NN <_SYM PPFP_NP <=_50%) 50_CD %_NN )_) ._SENT The_DT TC_NP patients_NNS were_VBD subdivided_VBN into_IN three_CD groups_NNS ,_, as_IN they_PP received_VBD treatment_NN during_IN the_DT acute_JJ (_( A_NP )_) ,_, subacute_JJ (_( SA_NP )_) ,_, or_CC chronic_JJ (_( C_NP )_) phase_NN of_IN the_DT disease_NN ._SENT FIG._NN 6_CD ._SENT |_SYM Analysis_NP of_IN PPFP_NP values_NNS from_IN patients_NNS with_IN negative_JJ xenodiagnosis_NN but_CC positive_JJ or_CC oscillating_VBG conventional_JJ serology_NN ._SENT Analysis_NN of_IN PPFP_NP values_NNS from_IN patients_NNS with_IN negative_JJ xenodiagnosis_NN but_CC positive_JJ or_CC oscillating_VBG conventional_JJ serology_NN ._SENT The_DT performance_NN of_IN FC-ALTA_NP for_IN samples_NNS from_IN the_DT TUE_NP patient_NN group_NN was_VBD investigated_VBN by_IN using_VBG FS_NN ,_, and_CC data_NNS analysis_NN was_VBD performed_VBN by_IN establishing_VBG a_DT 20_CD %_NN PPFP_NN value_NN as_IN the_DT cutoff_NN between_IN negative_JJ and_CC positive_JJ results_NNS ,_, as_RB described_VBN by_IN Martins-Filho_NP et_FW al._FW ._SENT Positive_JJ results_NNS were_VBD additionally_RB classified_VBN according_VBG to_TO the_DT method_NN of_IN Cordeiro_NP et_FW al._FW as_IN low_JJ positive_JJ (_( 20_CD %_NN <_SYM PPFP_NP <=_50%) 50_CD %_NN )_) ._SENT The_DT TC_NP patients_NNS were_VBD subdivided_VBN into_IN groups_NNS ,_, as_IN they_PP received_VBD treatment_NN during_IN the_DT acute_JJ (_( A_NP )_) or_CC chronic_JJ (_( C_NP )_) phase_NN of_IN the_DT disease_NN (_( b_LS )_) ,_, had_VBD positive_JJ or_CC oscillating_VBG serology_NN (_( a_DT )_) ,_, and_CC had_VBD less_JJR or_CC more_JJR than_IN 10_CD years_NNS of_IN follow-up_NN after_IN treatment_NN (_( c_LS )_) ._SENT Different_JJ studies_NNS performed_VBN with_IN either_DT human_JJ or_CC murine_JJ models_NNS have_VBP focused_VBN on_IN strategies_NNS to_TO evaluate_VB the_DT efficacy_NN of_IN specific_JJ chemotherapy_NN against_IN Chagas_NP '_POS disease_NN ._SENT Conflicting_JJ reports_NNS have_VBP arisen_VBN because_IN of_IN differences_NNS in_IN the_DT approaches_NNS applied_VBN as_IN cure_NN criteria_NNS ._SENT Positive_JJ parasitological_JJ tests_NNS indicate_VBP the_DT persistence_NN of_IN circulating_VBG parasites_NNS and_CC represent_VB a_DT definitive_JJ marker_NN of_IN ongoing_JJ infection_NN and_CC treatment_NN failure_NN ._SENT However_RB ,_, lack_NN of_IN sensitivity_NN is_VBZ the_DT major_JJ feature_NN that_WDT leads_VBZ to_TO a_DT low-negative_JJ predictive_JJ value_NN of_IN these_DT methods_NNS ._SENT On_IN the_DT other_JJ hand_NN ,_, most_JJS types_NNS of_IN CSA_NP tests_NNS ,_, evaluating_VBG the_DT presence_NN of_IN specific_JJ antibodies_NNS ,_, remain_VBP positive_JJ for_IN long_JJ periods_NNS after_IN treatment_NN ._SENT Therefore_RB ,_, despite_IN their_PP$ high_JJ sensitivity_NN ,_, CSA_NP tests_NNS are_VBP not_RB recommended_VBN as_IN cure_NN criteria_NNS ._SENT For_IN this_DT reason_NN ,_, there_EX is_VBZ an_DT urgent_JJ need_NN for_IN the_DT development_NN of_IN serological_JJ tests_NNS ,_, which_WDT avoid_VBP the_DT occurrence_NN of_IN positive_JJ serology_NN after_IN parasite_NN elimination_NN ._SENT One_CD of_IN the_DT strategies_NNS is_VBZ to_TO search_VB for_IN new_JJ immunological_JJ techniques_NNS ,_, which_WDT are_VBP more_RBR reliable_JJ ,_, to_TO be_VB used_VBN in_IN follow-up_NN studies_NNS after_IN treatment_NN ._SENT The_DT finding_NN of_IN two_CD types_NNS of_IN anti-T_NP ._SENT cruzi_NN antibodies_NNS (_( LA_NP and_CC CSA_NP )_) enabled_VBD Krettli_NP and_CC Brener_NP to_TO describe_VB a_DT phenomenon_NN of_IN serology_NN dissociation_NN and_CC postulate_NN that_IN the_DT absence_NN of_IN LA_NP should_MD be_VB considered_VBN a_DT cure_NN marker_NN ,_, despite_IN residual_JJ positive_JJ CSA_NP tests_NNS ._SENT Considering_VBG the_DT technical_JJ laboriousness_NN of_IN CoML_NP ,_, we_PP have_VBP used_VBN an_DT alternative_JJ tool_NN (_( FC-ALTA_NP )_) in_IN our_PP$ laboratory_NN that_WDT was_VBD shown_VBN to_TO be_VB comparable_JJ to_TO CoML_NP for_IN monitoring_VBG the_DT treatment_NN effectiveness_NN in_IN cases_NNS of_IN human_JJ Chagas_NP '_POS disease_NN ._SENT In_IN fact_NN ,_, the_DT sensitivity_NN of_IN FC-ALTA_NP was_VBD much_RB higher_JJR than_IN that_DT of_IN CoML_NP ,_, as_RB shown_VBN by_IN the_DT optimal_JJ dilutions_NNS required_VBN ,_, 1:256_CD and_CC 1:4_CD ,_, respectively_RB ._SENT Furthermore_RB ,_, the_DT capacity_NN of_IN flow_NN cytometry_NN to_TO count_VB thousands_NNS of_IN trypomastigotes_NNS per_IN assay_NN improved_VBD the_DT data_NN confidence_NN ._SENT Like_IN CoML_NP ,_, the_DT original_JJ FC-ALTA_NP method_NN allows_VBZ for_IN distinguishing_VBG sera_NN from_IN NT_NP and_CC TNC_NP patients_NNS from_IN both_DT TC_NP and_CC noninfected_JJ individuals_NNS ._SENT However_RB ,_, the_DT original_JJ FC-ALTA_NP let_VBP two_CD out_RP of_IN nine_CD TNC_NP patients_NNS with_IN positive_JJ CoML_NP results_NNS fall_VBP below_IN the_DT 20_CD %_NN cutoff_NN level_NN ._SENT For_IN this_DT reason_NN ,_, in_IN the_DT present_JJ investigation_NN we_PP designed_VBD an_DT optimization_NN of_IN the_DT original_JJ method_NN in_IN order_NN to_TO improve_VB its_PP$ performance_NN and_CC sensitivity_NN ._SENT Our_PP$ data_NNS demonstrated_VBD that_DT incubation_NN with_IN FITC-conjugated_NP anti-human_NP IgG_NP antibody_NN for_IN 30_CD min_NN at_IN 37C_JJ led_VBN to_TO higher_JJR PPFP_NP values_NNS for_IN samples_NNS from_IN chagasic_JJ patients_NNS ,_, with_IN no_DT changes_NNS for_IN samples_NNS from_IN cured_VBN individuals_NNS ._SENT Therefore_RB ,_, we_PP have_VBP incorporated_VBN this_DT adjustment_NN in_IN the_DT original_JJ method_NN for_IN further_JJR studies_NNS ._SENT Another_DT great_JJ advance_NN achieved_VBN by_IN this_DT study_NN was_VBD the_DT perspective_NN of_IN fitting_VBG the_DT method_NN for_IN field_NN surveys_NNS since_IN the_DT PPFP_NP values_NNS were_VBD not_RB adversely_RB affected_VBN when_WRB testing_NN GPS_NNS ._SENT Parallel_JJ analysis_NN of_IN FS_NP and_CC GPS_NP demonstrated_VBD that_IN only_RB 3_CD out_IN of_IN 70_CD samples_NNS showed_VBD discrepancies_NNS in_IN PPFP_NP values_NNS ._SENT From_IN those_DT ,_, only_RB two_CD samples_NNS interchanged_VBN between_IN negative_JJ and_CC low-positive_JJ results_NNS within_IN PPFP_JJ intervals_NNS of_IN 20_CD %_NN +-_NN 10_CD %_NN ._SENT Then_RB we_PP recommended_VBD that_IN when_WRB testing_NN GPS_NNS ,_, the_DT interpretation_NN of_IN PPFP_NP values_NNS should_MD take_VB this_DT variation_NN into_IN account_NN ._SENT In_IN the_DT study_NN described_VBD here_RB ,_, the_DT major_JJ goal_NN of_IN the_DT research_NN was_VBD to_TO conduct_VB a_DT double-blind_JJ investigation_NN to_TO reinforce_VB the_DT use_NN of_IN FC-ALTA_NP for_IN clinical_JJ survey_NN ._SENT For_IN this_DT purpose_NN ,_, we_PP tested_VBD coded_VBN serum_NN samples_NNS from_IN four_CD different_JJ categories_NNS of_IN chagasic_JJ patients_NNS ,_, including_VBG TC_NP ,_, TNC_NP ,_, TUE_NP ,_, and_CC NT_JJ patients_NNS ._SENT Our_PP$ data_NNS confirmed_VBD ,_, in_IN another_DT study_NN population_NN ,_, our_PP$ previous_JJ statement_NN that_IN patients_NNS with_IN ongoing_JJ infection_NN (_( NT_NP and_CC TNC_NP )_) ,_, in_IN this_DT case_NN identified_VBN by_IN positive_JJ xenodiagnosis_NN ,_, had_VBD positive_JJ results_NNS with_IN FC-ALTA_NP ._SENT It_PP was_VBD interesting_JJ that_IN the_DT optimization_NN of_IN the_DT original_JJ method_NN ,_, as_RB described_VBD above_RB ,_, held_VBD all_DT TNC_NP patient_NN samples_NNS with_IN PPFP_NP values_VBZ higher_JJR than_IN 20_CD %_NN ,_, improving_VBG the_DT performance_NN of_IN the_DT original_JJ technique_NN ,_, in_IN which_WDT 2_CD out_IN of_IN 9_CD TNC_NP patient_NN samples_NNS fell_VBD bellow_VB the_DT cutoff_NN level_NN ._SENT In_IN our_PP$ pioneer_NN study_NN ,_, we_PP suggested_VBD that_IN those_DT low_JJ PPFP_NP values_NNS should_MD be_VB the_DT result_NN of_IN antibody_NN shedding_VBG from_IN the_DT parasite_NN membrane_NN and_CC that_DT shorter_JJR incubation_NN times_NNS at_IN a_DT lower_JJR temperature_NN should_MD resolve_VB this_DT question_NN ._SENT Here_RB ,_, we_PP confirm_VBP that_IN lower_JJR incubation_NN time_NN but_CC higher_JJR temperature_NN was_VBD the_DT optimal_JJ condition_NN to_TO improve_VB the_DT sensitivity_NN of_IN FA-ALTA_NP with_IN no_DT effect_NN on_IN its_PP$ ability_NN to_TO discriminate_VB negative_JJ samples_NNS ._SENT Together_RB ,_, the_DT data_NNS from_IN NT_NP and_CC TNC_NP patient_NN samples_NNS reemphasizes_VBZ that_IN the_DT persistence_NN of_IN circulating_VBG parasites_NNS is_VBZ associated_VBN with_IN the_DT presence_NN of_IN ALTA_NP ,_, which_WDT can_MD be_VB used_VBN as_IN a_DT valid_JJ immunological_JJ marker_NN for_IN active_JJ infection_NN ._SENT Furthermore_RB ,_, it_PP should_MD be_VB stressed_VBN that_IN ,_, in_IN general_NN ,_, patients_NNS with_IN negative_JJ CSA_NP and_CC negative_JJ xenodiagnosis_NN persistently_RB had_VBD PPFP_JJ values_NNS under_IN 20_CD %_NN ._SENT Unexpectedly_RB ,_, we_PP found_VBD that_IN one_CD cured_VBN patient_NN had_VBD PPFP_JJ values_NNS over_IN 50_CD %_NN in_IN sequential_JJ samples_NNS and_CC repeated_JJ tests_NNS ._SENT Interestingly_RB ,_, we_PP found_VBD that_IN this_DT patient_NN had_VBD been_VBN treated_VBN for_IN tuberculosis_NN 10_CD years_NNS before_IN inclusion_NN in_IN this_DT study_NN ._SENT This_DT patient_NN had_VBD more_JJR than_IN 140_CD negative_JJ xenodiagnoses_NNS and_CC persistent_JJ negative_JJ CSA_NP results_NNS over_IN the_DT past_JJ 10_CD years_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Several_JJ studies_NNS have_VBP reported_VBN the_DT possibility_NN of_IN cross-reactivity_NN in_IN the_DT serology_NN for_IN Chagas_NP '_POS disease_NN in_IN patients_NNS with_IN tuberculosis_NN ._SENT We_PP are_VBP now_RB testing_VBG to_TO see_VB if_IN samples_NNS from_IN patients_NNS with_IN tuberculosis_NN may_MD present_VB cross-reactivity_NN in_IN FC-ALTA_NP assay_NN ._SENT Considering_VBG these_DT observations_NNS ,_, we_PP suggest_VBP the_DT association_NN of_IN FC-ALTA_NP with_IN other_JJ tests_NNS already_RB indicated_VBD as_RB cure_VB criteria_NNS to_TO evaluate_VB therapeutic_JJ efficacy_NN in_IN Chagas_NP '_POS disease_NN ._SENT Parasitological_JJ and_CC CSA_NP tests_NNS should_MD be_VB performed_VBN repeatedly_RB before_IN a_DT single_JJ FC-ALTA_NP ._SENT Individuals_NNS presenting_VBG negative_JJ results_NNS on_IN conventional_JJ tests_NNS should_MD be_VB considered_VBN cured_VBN ,_, without_IN requirement_NN of_IN confirmation_NN by_IN FC-ALTA_NP ._SENT However_RB ,_, the_DT FC-ALTA_NP should_MD be_VB indicated_VBN ,_, to_TO confirm_VB cure_NN ,_, in_IN cases_NNS of_IN individuals_NNS with_IN several_JJ negative_JJ parasitological_JJ tests_NNS and_CC positive_JJ or_CC oscillating_VBG CSA_NP tests_NNS (_( TUE_NP patients_NNS )_) ,_, since_IN this_DT approach_NN could_MD save_VB several_JJ years_NNS of_IN inconclusive_JJ diagnosis_NN ._SENT In_IN fact_NN ,_, we_PP have_VBP found_VBN that_IN seven_CD samples_NNS within_IN the_DT TUE_NP patient_NN population_NN had_VBD negative_JJ PPFP_NP results_NNS and_CC could_MD be_VB classified_VBN as_IN dissociated_VBN according_VBG to_TO the_DT Krettli_NP and_CC Brener_NP criteria_NNS ._SENT As_IN previously_RB described_VBN ,_, these_DT individuals_NNS should_MD be_VB considered_VBN cured_VBN since_IN they_PP had_VBD negative_JJ results_NNS for_IN xenodiagnosis_NN and_CC PPFP_NP ._SENT We_PP therefore_RB postulated_VBD that_IN patients_NNS who_WP have_VBP been_VBN treated_VBN and_CC show_VB negative_JJ parasitological_JJ tests_NNS and_CC the_DT absence_NN of_IN ALTA_NP should_MD be_VB considered_VBN cured_VBN despite_IN residual_JJ positive_JJ or_CC oscillating_VBG CSA_NP ._SENT Here_RB ,_, using_VBG a_DT 1:256_CD serum_NN dilution_NN from_IN a_DT TUE_NP patient_NN ,_, we_PP have_VBP observed_VBN that_IN a_DT period_NN of_IN 10_CD years_NNS after_IN treatment_NN was_VBD required_VBN to_TO identify_VB negative_JJ results_NNS with_IN FC-ALTA_NP for_IN patients_NNS treated_VBN during_IN the_DT chronic_JJ phase_NN of_IN the_DT disease_NN ._SENT Then_RB ,_, we_PP hypothesized_VBD that_IN FC-ALTA_NP follow-up_NN with_IN serial_JJ dilution_NN could_MD identify_VB the_DT antibody_NN clearance_NN sooner_RBR by_IN the_DT shift_NN of_IN positive_JJ PPFP_NP values_NNS to_TO lower_JJR titers_NNS ._SENT This_DT hypothesis_NN is_VBZ currently_RB under_IN investigation_NN in_IN our_PP$ laboratory_NN ._SENT Finally_RB ,_, our_PP$ study_NN optimized_VBD and_CC validated_VBD our_PP$ method_NN ,_, offering_VBG another_DT tool_NN ,_, less_RBR laborious_JJ than_IN CoML_NP and_CC parasitological_JJ tests_NNS ,_, for_IN investigating_VBG and_CC monitoring_VBG results_NNS of_IN specific_JJ chemotherapy_NN ._SENT Furthermore_RB ,_, these_DT data_NNS reinforce_VBP the_DT relevance_NN of_IN studies_NNS regarding_VBG etiological_JJ treatment_NN of_IN chronic_JJ patients_NNS since_IN a_DT considerable_JJ number_NN of_IN successful_JJ treatments_NNS were_VBD achieved_VBN during_IN the_DT chronic_JJ phase_NN of_IN Chagas_NP '_POS disease_NN ._SENT 